Clinical Trials Logo

Clinical Trial Summary

Lipodystrophy Connect is an online survey tool designed to collect demographic data and health information from individuals with Lipodystrophy.


Clinical Trial Description

Lipodystrophy is a heterogeneous group of rare and inherited syndromes characterized by the complete or partial loss or absence of subcutaneous adipose tissue. People living with lipodystrophy lack the fat tissue required for normal metabolic function. To enhance knowledge of the underlying biology of these conditions and to institute effective clinical treatments, the Lipodystrophy community has developed a mechanism for individuals with any of the Lipodystrophy conditions to enroll in a Lipodystrophy registry called Lipodystrophy Connect. The objective of such a registry is to create a platform that connects all of the Lipodystrophy community, including persons with Lipodystrophy, family members, healthcare providers, researchers, drug companies, advocacy groups, federal research organizations, and regulators. A patient registry will provide the foundation for a resource to meet the current and future needs of the Lipodystrophy community as well as accelerate the rate of research and development of therapies that improve the quality of life of those with Lipodystrophy. Lipodystrophy Connect is an online survey tool that collects basic demographic information and health information from people with any rare form of Lipodystrophy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02577952
Study type Observational [Patient Registry]
Source PatientCrossroads
Contact
Status Completed
Phase
Start date January 2014
Completion date November 8, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT05419037 - Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy
Recruiting NCT03059121 - The Cleveland Cardiometabolic Cohort
Completed NCT00656175 - Raltegravir Therapy for Women With HIV and Fat Accumulation Phase 2
Completed NCT00006185 - Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome Phase 1
Completed NCT00202241 - The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS N/A
Recruiting NCT02262832 - Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy Phase 3
Completed NCT01679197 - Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy Phase 2
Completed NCT02647853 - Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers Phase 1
Active, not recruiting NCT00715546 - Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy Phase 1
Completed NCT00069004 - A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth N/A
Completed NCT00025883 - Leptin to Treat Lipodystrophy Phase 2
Completed NCT00001142 - Metabolism and Body Shape of Healthy Children and Children With Chronic Infections N/A
Active, not recruiting NCT02262806 - Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy Phase 2
Completed NCT02258685 - Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients.
Completed NCT00192621 - Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects Phase 4
Completed NCT00006190 - A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy Phase 4
Recruiting NCT05930106 - Carotid Doppler Peak Velocity Variation in Liposuction Fluid Management N/A
Completed NCT00004329 - Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy N/A
Recruiting NCT04656054 - Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance
Completed NCT00082628 - Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients Phase 3